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Abstract The DNA sequence encoding a novel human brain
carboxylesterase (CES) has been determined. The protein is
predicted to have 567 amino acids, including conserved motifs,
such as GESAGG, GXXXXEFG, and GDHGD which comprise
a catalytic triad, and the endoplasmic reticulum retention motif
(HXEL-COOH) observed in CES families. Their gene products
exhibited hydrolase activity towards temocapril, p-nitrophenyl-
acetate and long-chain acyl-CoA. Since the molecular masses of
these gene products are similar to those that exist in capillary
endothelial cells of the human brain [Yamamda et al. (1994)
Brain Res. 658, 163^167], these CES isozymes may function as a
blood-brain barrier to protect the central nervous system from
ester or amide compounds.
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1. Introduction
Mammalian carboxylesterases (CESs, EC 3.1.1.1) comprise
a multigene family whose gene products exist in many mam-
malian species and humans [1]. These enzymes are glycopro-
teins of the high mannose-containing type, and N-glycosyla-
tion may play an important role in the catalytic activity of
CESs [2]. We recently described that a number of CES iso-
zymes from mammals and humans are glycoproteins of high-
mannose type [1]. These enzymes e⁄ciently catalyze the hy-
drolysis of a variety of drugs or prodrugs containing ester and
amide bonds [3]. Since ester derivatives of therapeutic agents
have been used as prodrugs, CES is a major determinant of
the pharmacokinetic behavior of most prodrugs, and its ac-
tivity can be in£uenced by direct interactions with a variety of
compounds either directly or at the level of enzyme regulation
[3,4]. The enzyme also hydrolyzes endogenous long-chain fatty
acid esters or thioesters [5^8]. Therefore, CES may play an
important role in lipid metabolism as well as in drug metab-
olism.
Recently, we reported that human brain CES preparations
were immunocross-reactive with human anti-liver CES anti-
bodies [9]. The presence of CES in endothelial cells of the
human brain has been established by immunohistochemistry
using anti-human liver CES antibodies, suggesting the pres-
ence of similar isozymes in the central nervous system and the
liver. Capillary endothelial cells of the brain function as a
dynamic interface with regard to the transfer of nutrients
and drugs from the circulation to brain interstitial £uid [10].
Therefore, the presence of CESs in capillary endothelial cells
may be consistent with the enzyme acting to protect the cen-
tral nervous system from toxic esters, a component of the so-
called blood-brain barrier system. Since a signi¢cant number
of drugs are metabolized by CES, altering the activity of en-
dothelial CES may have important clinical implications. How-
ever, little is known about the di¡erences in structure and
hydrolytic capability of CES isozymes expressed in the brain
of humans.
In the present study, we cloned and characterized novel
CES cDNAs from the human brain, and we undertook the
structural characterization of CES isozymes expressed in the
human brain in order to learn more about the molecular basis
responsible for their functional di¡erences in drug and lipid
metabolism.
2. Materials and methods
2.1. cDNA cloning of human brain CES
For isolation of cDNA encoding CES isozymes from the human
brain, a Vgt 11 cDNA library (Clontech Laboratories, CA, USA) was
screened according to the general method using nitrocellulose ¢lters
with either antibodies to human liver CES HU1 [11] or hybridization
with a coding region of CES HU1 cDNA [12] (PCR ampli¢ed using
5P-CTGAAAACACCTGAAGAGCTTCAA-3P and 5P-CTCCCAAG-
GCCGGCTGGATCTTCA-3P) as a probe labeled with the ECL di-
rect nucleic acid labeling and detection system (Amersham Pharmacia
Biotech, Uppsala, Sweden). Inserts in phage DNAs of positive clones
were isolated by EcoRI restriction and subcloned into plasmid pUC
118. To identify the 5P end of the CES gene, 5P-RACE PCR was
performed using total RNA from the human brain (Clontech) and a
Marathon cDNA ampli¢cation kit (Clontech). The antisense primer
was made according to the hBr0-13 clone, and the sequence was
5P-ATCCCCTGTGCTGAAGAATCC-3P. In order to obtain the full
length of the CES cDNA, PCR ampli¢cation was performed, the
sense primer was made according to the hBr5-3-20 clone (5P-CAC-
AATGCGCCTCTACCCTC-3P) and the antisense primer was made
according to the hBr0-13 clone (5P-GGAGCCGCCCATYCAAAGC-
3P). The ampli¢ed DNA (hBr3) was subcloned into a pTARGET
vector (Promega, OR, USA).
Nucleotide sequences were determined by the dideoxy method using
a Thermo Sequenase £uorescent labelled primer cycle sequencing kit
with 7-deaza-dGTP (Amersham Pharmacia Biotech) and an auto-
mated DNA sequencer (Shimadzu DSQ-2000 system, Shimazu, Kyo-
to, Japan).
2.2. Transfection and G418 selection
The parental V79 cells (V79-4, American Type Culture Collection
CL93, Rockville, MD, USA) were cultured in Dulbecco’s modi¢ed
0014-5793 / 99 / $20.00 ß 1999 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 9 ) 0 1 1 1 1 - 4
*Corresponding author. Fax: (81) (43) 290-2921.
E-mail: masakiyo@p.chiba-u.ac.jp
1 The nucleotide sequence data reported in this paper will appear in
the DDBJ, EMBL, and GenBank nucleotide sequence databases with
accession numbers AB025026 and AB025028.
Abbreviations: CES, carboxylesterase; D-MEM, Dulbecco’s modi¢ed
Eagle’s medium; HPLC, high-performance liquid chromatography;
5P-RACE, 5P-rapid ampli¢cation of cDNA end
FEBS 22555 1-9-99
FEBS 22555 FEBS Letters 458 (1999) 17^22
Eagle’s medium (D-MEM; Gibco, Grand Island, NY, USA) supple-
ment with 10% heat inactivated fetal bovine serum (Gibco), penicillin/
streptomycin (Gibco) and L-glutamine (Gibco) in an atmosphere of
5% CO2 and 95% air at 37‡C. The V79 cells were plated at 1U106
cells/100 mm plate. The next day, 10 Wg of vector DNA (hBr3/pTAR-
GET, HU1/pTARGET or pTARGET) was transfected into the cells
using SuperFect Transfection Reagent (Qiagen, Hilden, Germany)
with OPTI-MEM medium (Gibco). On day 3, the cells were split
into 100 mm plates with media containing the selective agent, G418
(Gibco), at 400^800 Wg/ml. The medium was changed every 2^3 days,
and the cells were maintained for at least 3 weeks to obtain stable
expression colonies. Ten colonies were identi¢ed and homogenized by
SET bu¡er (0.25 M sucrose, 1 mM EDTA, 100 mM Tris-HCl bu¡er,
pH 7.4), and the expression of hBr3 or HU1 was determined by
examining p-nitrophenylacetate, long-chain acyl-CoA and temocapril
hydrolase activities or by immunoblot analysis. These G418-resistant
colonies could be stored in liquid N2 for several months without loss
of expression level.
2.3. Enzyme assays
Temocapril hydrolase activity was determined as follows. An assay
mixture consisting of 50 Wl of 200 mM HEPES bu¡er (pH 7.4), 50 Wl
of cell homogenate at a suitable concentration, 100 Wl of temocapril
solution (100 WM or 500 WM in water; ¢nal concentration of 50 WM
or 250 WM, respectively) was incubated at 37‡C for 20^40 min. The
reaction was performed in a linear range with respect to protein con-
centration and incubation time. After the reaction was stopped by
addition of 200 Wl of cold ethanol, the mixture was centrifuged at
10 000Ug for 15 min, and 200 Wl of the supernatant was analyzed
by HPLC as described below.
The hydrolytic metabolite of temocapril, temocaprilat, was deter-
mined using the following HPLC method. The HPLC system con-
sisted of a model L-6000 pump (Hitachi, Tokyo, Japan), a model
L4000H UV detector (Hitachi), a model AS-2000 autosampler (Hita-
chi), a model D-2500 integrator (Hitachi), and a 4.6U150 mm YMC-
Pack Ph A-402 column (YMC, Tokyo, Japan). For the determination
of temocaprilat, the mobile phase consisted of 0.2% phosphoric acid-
acetonitrile (60:40, v/v) and was delivered at a £ow rate of 0.8 ml/min.
The eluate was monitored at a wavelength of 233 nm. A calibration
curve was generated from 5 to 250 WM by processing the authentic
standard substance through the entire procedure. Temocapril and
temocaprilat were kindly obtained from Dr. Toshihiko Ikeda, Ana-
lytical and Metabolic Research Laboratories, Sankyo Co., Hiromachi,
Shinagawa-ku, Tokyo, Japan. Michaelis-Menten kinetic parameters
(Km and Vmax) for p-nitrophenylacetate hydrolase activity were esti-
mated by non-linear least-squares regression analysis. p-Nitrophenyl-
acetate and long-chain acyl-CoA hydrolase activities were determined
as described previously [5].
2.4. Immunoblotting
Immunoblot analysis was performed as reported previously [5].
Brie£y, puri¢ed CES isozymes (0.2 Wg/well) and V79 cell homogenates
(5 Wg/well) were electrophoresed on SDS-polyacrylamide gels, trans-
ferred onto a nitrocellulose sheet, and stained immunochemically.
3. Results and discussion
3.1. Screening of a cDNA library
A Vgt11 cDNA library, constructed from the human brain,
was screened by plaque hybridization using a 1093 bp PCR
fragment of CES cDNA prepared from human liver [2,12].
From 1.8U105 plaques tested, 12 positive clones were iso-
lated, and the cDNA insert was subcloned into pUC118 and
sequenced with Thermo Sequenase DNA polymerase and £u-
orescent labeled primer using an automated DNA sequencer.
These clones contained cDNA inserts of 0.5^1.3 kb. The larg-
est clone, designated hBr0-13, spanned 1285 bp, with an open
reading frame encoding a 345 amino acid polypeptide, fol-
lowed by a termination codon (TAG), and followed in turn
by 251 nucleotides of a 3P-non-coding sequence which con-
tained a consensus polyadenylation signal (AATAAA) and a
69 bp long poly(A) tail (data not shown). The authenticity of
the coding region of hBr0-13 cDNA was supported by match-
ing its deduced amino acid sequence with conserved motifs in
mammalian CESs. The clone showed 71.5% homology to the
human liver CES isozyme HU1 [12] or hCE [2].
However, hBr0-13 did not contain an in-frame initiation
codon (ATG), suggesting that this cDNA lacked part of the
5P end of the coding region. To obtain a cDNA corresponding
to this missing region, 5P-RACE-Marathon-Ready cDNA,
prepared from human brain total RNA, was ampli¢ed by
5P-RACE according to the instructions of the manufacturer
(Clontech). As a result, ¢ve cDNAs of di¡erent lengths be-
tween 465 bp and 1359 bp were obtained and were subcloned
into a pGEM-T vector (Promega) by TA cloning methods and
then sequenced. A 1298 bp 5P-RACE PCR product (hBr5-3-
20) had a start codon and open reading frame consisting of
431 amino acids, which overlapped with the cDNA of hBr0-
13 by 620 bp. To obtain the full-length cDNA sequence of
human brain CES, further PCR was performed using the
sense primer from hBr5-3-20 and the antisense primer from
hBr0-13, and a ¢nal PCR product designated hBr3 was iso-
lated. hBr3 was subcloned into a pTARGET vector and se-
quenced. We also obtained another 1359 bp 5P-RACE PCR
product designated hBr1, which had a start codon and open
reading frame consisting of 429 amino acids. However, the
hBr1 did not completely overlap the 5P end of hBr0-13. The
homology of this nucleotide sequence with hBr3 is 71%, and
the clone did not include a stop codon. Although we tried to
C
Fig. 1. The nucleotide and the deduced amino acid sequence of human brain CES hBr3. A putative signal peptide is indicated by dotted under-
lining. The arrow shows the putative restriction site of the signal peptidase. Ser (S), Glu (E) and His (H), which are presumed to be the active
sites (#), potential glycosylation sites (*) and cysteine ($), are labeled. The box shows the conserved catalytic triad. The C-terminal retention
signal is indicated by single underlining.
Table 1
Catalytic activity of xenobiotic or endogenous substrates in V79 cells expressing CES isozymes
Substrate Hydrolase activity (nmol/mg/min)
hBr3/pTARGET HU1/pTARGET
p-Nitrophenylacetate 200.8 43.8
Temocapril 0.260 0.070
Palmitoyl-CoA 6.14 0.05
Oleoyl-CoA 20.9 1.35
hBr3/pTARGET: hBr3/pTARGET-transfected V79 cells; HU1/pTARGET: HU1/pTARGET- transfected V79 cells.
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obtain full-length cDNA of hBr1 by 3P-RACE methods, we
were not successful.
3.2. Nucleotide and amino acid sequence of hBr3
The nucleotide and deduced amino acid sequence of hBr3
are shown in Fig. 1. The deduced amino acid sequence of
hBr3 was not identical to any reported sequence in the data-
base. The cDNA is 1722 bp long with an open reading frame
of 1701 bp encoding a polypeptide of 567 amino acid residues
(i.e. 18 amino acid residues for a signal peptide and 549 amino
acid residues for a mature subunit). The nucleotide sequence
surrounding the ¢rst ATG codon was a putative start site for
translation, being located in the consensus sequence for eu-
karyotic initiation codes [13].
The deduced amino acid sequence of hBr3 contained several
motifs characterizing CES isozymes and other serine hydro-
lases [3,14]. For example, it contained four Cys residues, in-
cluding Cys-98, in the structure of the polypeptide responsible
for the mature subunit, and one residue in the presumed sig-
nal peptide. These Cys residues, except the one in the signal
peptide, are highly conserved in most CES isozymes and may
function as speci¢c disul¢de bonds. Among them, Cys-98 is
the most highly conserved in CES and other serine hydrolases
and has been proposed to be one of the structurally important
amino acid residues in esterase, lipase and related enzymes, on
the basis of X-ray structures of Torpedo californica acetylcho-
linesterase and Geotrichum candidum lipase [14]. Another mo-
tif characterizing CES is the two Asn residues at positions 61
and 472 in the N-X-S/T motif, which is known to be a puta-
tive N-glycosylation site. The amino acid sequence of hBr3
also contains common structures of serine hydrolase super-
families, Ser-203 (GESAGG), Glu-335 (GXXXXEXG) and
His-449 (GDHXD), which comprise a catalytic triad and
Gly-123^Gly-124, which may be a part of the oxyanion hole
[3]. This cDNA clone also encoded the same structure as the
endoplasmic reticulum retention motif (HXEL-COOH) ob-
served in CES families [3]. Since several proteins of the endo-
plasmic reticulum lumen have a similar carboxy-terminal se-
quence (KDEL-COOH) which binds the KDEL receptor to
be retained in the endoplasmic reticulum, the polypeptide en-
Fig. 2. Alignment of the predicted amino acid sequences of human brain CES hBr3, with human brain CES hBr1 (present study), human liver
CES HU1 [12] and human intestine CES iCE [16]. Identical amino acid residues are shown in gray boxes.
Fig. 3. Immunoblot analysis of human liver microsomes, human liv-
er and brain CES cDNA-transfected V79 cells and puri¢ed human
liver CES HU1 with antibodies to human liver CES HU1. 1, HU1/
pTARGET-transfected V79 cells; 2, hBr3/pTARGET-transfected
V79 cells; 3, puri¢ed human liver CES HU1.
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coded by hBr3 is considered to be localized on the luminal
side of the endoplasmic reticulum [15].
3.3. Comparison of the deduced amino acid sequences of hBr3
and other carboxylesterases
Fig. 2 shows the alignment of the deduced amino acid se-
quences of the human brain hBr3 and hBr1, human liver CES
HU1 [12], and human intestine iCE [16]. Ser-203, Glu-335,
and His-447, which constitute a catalytic triad, are highly
conserved in these isozymes. In addition, four Cys involved
in disul¢de bonds and the endoplasmic reticulum retention
motif HXEL-COOH are also conserved. The sequence of
hBr3 showed 76%, 76%, and 50% amino acid sequence iden-
tity with hBr1, HU1, and iCE, respectively.
In contrast, the deduced amino acid sequence of hBr1 was
almost identical to that of human liver CES HU1 [12] and
hCE [2], having a sequence identity of more than 99% (Fig. 2).
Therefore, hBr3, HU1 and hCE are considered to be the same
gene product.
3.4. Stable expression of hBr3 and HU1 in V79 cells
The cDNAs for hBr3 and human liver CES HU1 were
inserted separately into the pTARGET mammalian expres-
sion vector (hBr3/pTARGET and HU1/pTARGET, respec-
tively) and transfected into V79 cells. As shown in Fig. 3,
immunoblot analysis of the cell extracts from pTARGET-,
hBr3/pTARGET- and HU1/pTARGET-transfected V79 cells
with anti-human liver CES HU1 antibodies gave protein
bands that were approximately 60 kDa. These results suggest
that both the cDNA of hBr3 and that of HU1 were stably
expressed in V79 cells and that these two gene products (CES
hBr3 and CES HU1) were immunocross-reactive with anti-
human liver CES HU1 antibodies. Previously, we reported
that human brain preparations were immunocross-reactive
with human anti-liver CES antibodies and that the position
of migration is the same as that of human liver preparations
in immunoblotting analysis [9]. We also showed by immuno-
histochemistry using anti-human liver CES antibodies that
CES was expressed in capillary endothelial cells of the human
brain [9]. These ¢ndings coupled with the present results sug-
gest that gene products of hBr3 and/or hBr1 are immuno-
cross-reactive with anti-HU1 antibodies, which have been re-
ported to be distributed in capillary endothelial cells of the
human brain.
Table 1 shows the hydrolysis activities of p-nitrophenylace-
tate and temocapril, a prodrug of an angiotensin-converting
enzyme inhibitor, in cell extracts of V79 cells expressing CES
hBr3 or CES HU1. Both activities were much higher in cells
expressing CES hBr3 than those expressing CES HU1,
although the expression level of CES hBr3 was commensurate
with that of CES HU1 (data not shown). Table 2 shows the
kinetic parameters of the hydrolysis of p-nitrophenylacetate
by V79 cells expressing CES hBr3 and CES HU1. The V79
cells expressing CES hBr3 showed a lower Michaelis constant
(Km) and higher Vmax, so that the Vmax/Km values for p-nitro-
phenylacetate hydrolysis were much higher than those of CES
HU1. Similarly, V79 cells expressing CES hBr3 showed much
higher temocapril hydrolase activity than CES HU1 in 5^500
WM substrate concentration (data not shown). The results
suggest that CES hBr3 possesses a di¡erent catalytic property
from CES HU1, and this may be caused by the structural
di¡erence in the amino acid sequences (Fig. 2).
Table 1 also shows the hydrolysis of endogenous substrates
by CES hBr3 and CES HU1. We previously reported that the
most e¡ectively metabolized endogenous substrate of CES
was the long-chain acyl-CoAs [5]. Therefore, hydrolysis of
acyl-CoAs of di¡erent acyl chain lengths was tested in the
present study. The V79 cells expressing CES hBr3 showed
high hydrolytic activity toward oleoyl-CoA (Table 1); how-
ever, acyl-CoAs of medium chain length were poorly, or
not, hydrolyzed by CES hBr3 (data not shown). These results
suggest that the human brain CES isozyme possesses similar
substrate speci¢city toward acyl-CoAs reported previously
and may play an important role in lipid metabolism in the
brain.
Although the physiological function of brain CES isozymes
remains unclear, Ishizuka et al. [17] reported that temocapri-
lat, which is a hydrolytic metabolite of temocapril, is trans-
ported by a canalicular multispeci¢c organic anion transporter
(cMOAT). In addition, Kusuhara et al. [18] reported that an
organic anion transporter exists in brain capillary endothelial
cells and suggested that the transporter is responsible for the
unidirectional, energy-dependent e¥ux of organic anions from
the brain into the circulating blood across the blood-brain
barrier. Therefore, the brain CESs in capillary endothelial
cells may cooperate with these transporters for e¥uxing or-
ganic anions that are produced in the brain to the circulating
blood through the metabolism via CES.
In conclusion, we isolated and sequenced two cDNA clones
encoding CES, referred to as hBr1 and hBr3, from a human
brain cDNA library. The latter clone was a novel one but the
former was considered to be the same as human liver CES
HU1. Although the physiological function of these brain CES
isozymes remains unclear, they may exist in capillary endo-
thelial cells of the human brain and may function as a blood-
brain barrier by co-operating with a multidrug resistance fam-
ily of transporters that e¥ux organic anions from the brain
into the circulating blood.
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